# Loxo Oncology

Source: https://onco.cc/companies/loxo-oncology/  
OnCo record `loxo-oncology` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Loxo Oncology developed pills aimed at single gene changes that drive some cancers, including selpercatinib for RET-altered cancers and pirtobrutinib for some blood cancers. Eli Lilly bought the company in 2019.

## Summary

Loxo Oncology, Inc. (formerly Nasdaq: LOXO), based in Stamford, Connecticut, developed highly selective medicines for cancers driven by a single genetic change that can be found by genomic testing. When Eli Lilly agreed to buy it on 7 January 2019, its portfolio included LOXO-292 (later selpercatinib), an oral RET inhibitor with FDA Breakthrough Therapy designation; LOXO-305 (later pirtobrutinib), an oral BTK inhibitor in phase 1/2 designed to work after resistance to existing BTK inhibitors; Vitrakvi (larotrectinib), a TRK inhibitor developed and sold with Bayer; and LOXO-195, a follow-on TRK inhibitor. Lilly paid USD 235 per share in cash, about USD 8.0 billion, through a tender offer, and the merger was completed on 15 February 2019.

## Fields

- Kind: Company
- Last checked: 2026-11-03
- Also known as: Loxo Oncology, Inc.; NASDAQ:LOXO
- HQ: Stamford, CT
- Type: biotech

## Notes

- Lilly's own record is named 'Eli Lilly (incl. Loxo)'; this record holds the company before and at the acquisition. Larotrectinib is linked as a Loxo product because the announcement describes it as developed and commercialised by Loxo with Bayer. Completion on 15 February 2019 is from Loxo's 8-K of that date. No website or founding year is recorded.

## Sources

- Lilly announces agreement to acquire Loxo Oncology (8-K exhibit 99.1, 7 January 2019): https://www.sec.gov/Archives/edgar/data/1581720/000119312519003083/d674169dex991.htm
- Form 8-K: completion of the merger (15 February 2019): https://www.sec.gov/Archives/edgar/data/1581720/000119312519042505/d664418d8k.htm

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [BTK (Bruton tyrosine kinase)](https://onco.cc/targets/btk/), [NTRK](https://onco.cc/targets/ntrk/), [RET](https://onco.cc/targets/ret/)
- drugs: [Larotrectinib](https://onco.cc/drugs/larotrectinib/), [Pirtobrutinib](https://onco.cc/drugs/pirtobrutinib/), [Selpercatinib](https://onco.cc/drugs/selpercatinib/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/loxo-oncology.json